Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

March 31, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

FCN-011

FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai